Sudeep Pharma Ltd Hits All-Time High of Rs 1,025.35 as Momentum Builds Across Timeframes

49 minutes ago
share
Share Via
Sudeep Pharma Ltd, a player in the Pharmaceuticals & Biotechnology sector, achieved a significant milestone on 10 August 2026 as its stock price surged to an all-time high of Rs.1025.35. This marks a notable peak in the company’s market performance, reflecting sustained strength amid a challenging market environment.
Sudeep Pharma Ltd Hits All-Time High of Rs 1,025.35 as Momentum Builds Across Timeframes

Record-Breaking Price Movement

On 10 August 2026, Sudeep Pharma Ltd’s share price reached Rs.1025.35, surpassing its previous 52-week high of Rs.1015.00. The stock opened with a gap up of 3.87% and recorded an intraday high gain of 7.02%, closing with a robust day change of 6.15%. This performance notably outpaced the Pharmaceuticals & Biotechnology sector, which the stock outperformed by 6.58% on the same day.

The stock’s upward momentum is further supported by its position above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a strong technical foundation underpinning the rally.

Comparative Performance Against Benchmarks

Sudeep Pharma Ltd’s recent price trajectory has been impressive relative to the broader market. Over the past week, the stock surged 17.09%, while the Sensex declined marginally by 0.37%. The one-month gain stands at 23.51%, significantly outperforming the Sensex’s 1.01% rise. Over three months, the stock soared 54.10%, dwarfing the Sensex’s 1.32% increase.

Year-to-date, Sudeep Pharma Ltd has delivered a remarkable 68.81% return, contrasting sharply with the Sensex’s decline of 8.06%. This strong relative performance highlights the stock’s resilience and appeal within its sector and the broader market context.

Valuation Metrics Reflect Premium Pricing

As of 10 August 2026, the stock traded at Rs.1,017.00 with valuation multiples indicating a premium market positioning. The trailing twelve months (TTM) price-to-earnings (P/E) ratio stands at 59x, while the price-to-book value (P/BV) ratio is 12.25x. Enterprise value multiples are also elevated, with EV/EBITDA at 48.92x and EV/EBIT at 52.42x, reflecting investor willingness to pay a premium for the company’s earnings and operational cash flows.

The dividend yield remains modest at 0.16%, with the latest dividend declared at Rs.1.50 per share, paid on 23 July 2026. The dividend payout ratio data is not available, but the company’s focus appears to be on reinvestment and growth.

Technical Analysis Indicates Mildly Bullish Trend

Technical indicators provide a cautiously optimistic outlook. The overall trend is classified as mildly bullish since 3 July 2026, when the stock price crossed ₹866.45. Key technical signals such as MACD and Bollinger Bands are bullish, while the Relative Strength Index (RSI) currently shows no clear signal. On-balance volume (OBV) trends are mildly bullish on both weekly and monthly timeframes.

Immediate support is identified at the 52-week low of ₹524.95, while resistance levels include the 20-day moving average at ₹873.62 and the 100-day moving average at ₹737.64. The stock’s recent breakout above these levels has contributed to the new all-time high.

Quality Assessment Highlights Financial Strength

Sudeep Pharma Ltd’s quality assessment reflects a solid financial foundation. The company boasts a strong return on capital employed (ROCE) averaging 24.88%, indicating efficient use of capital. Interest coverage is robust at 33.98x, underscoring the company’s ability to service debt comfortably. Capital structure is excellent, with low leverage and no promoter share pledging, enhancing financial stability.

However, growth metrics over the past five years show no increase in sales or EBIT, suggesting a period of stagnation in top-line and operating profit expansion. Institutional holdings stand at a moderate 17.46%, reflecting a balanced ownership structure.

Recent Financial Trends Show Mixed Signals

In the short term, the company’s financial trend is flat as of June 2026. Positive developments include a 31.99% growth in profit after tax (PAT) for the nine months ending recently, reaching ₹136.89 crores, and a 20.58% increase in net sales over the latest six months, amounting to ₹340.61 crores.

Conversely, interest expenses have risen by 30.43% to ₹4.50 crores in the same period, and quarterly PAT has declined by 6.2% compared to the previous four-quarter average. These factors suggest some pressure on profitability despite top-line growth.

Delivery Volumes and Market Activity

Delivery volumes have shown a positive trend with a 26.83% increase over the past month and a 2.93% rise on the latest trading day compared to the five-day average. On 6 August 2026, delivery volume was recorded at 2.07 lakh shares, representing 30.53% of total volume, slightly below the five-day average of 2.13 lakh shares (36.75%). This indicates sustained investor participation in the stock’s upward movement.

Market Capitalisation and Mojo Rating

Sudeep Pharma Ltd is classified as a small-cap company within the Pharmaceuticals & Biotechnology sector. The MarketsMOJO rating system assigned the stock a Mojo Score of 58.0 and a Mojo Grade of ‘Hold’ as of 22 May 2026, marking the first formal rating after a period of no rating. This grade reflects a balanced view of the company’s valuation and quality metrics.

Summary of the Stock’s Journey to the Peak

The stock’s ascent to an all-time high is the culmination of sustained price appreciation supported by strong relative performance against the Sensex and sector benchmarks. The technical breakout above key moving averages and resistance levels has been accompanied by solid delivery volumes and a stable quality profile. While valuation multiples remain elevated, they are consistent with the company’s premium positioning in the pharmaceuticals sector.

Financial trends reveal a mixed picture with robust sales and PAT growth over recent periods, tempered by rising interest costs and a slight dip in quarterly profitability. The company’s strong capital structure and efficient capital utilisation provide a foundation for maintaining its market standing.

Conclusion

Sudeep Pharma Ltd’s stock reaching Rs.1025.35 on 10 August 2026 marks a significant milestone in its market history. The achievement reflects a combination of favourable market dynamics, technical strength, and solid financial underpinnings. This all-time high underscores the company’s established presence within the Pharmaceuticals & Biotechnology sector and highlights its capacity to deliver notable shareholder value over the recent period.

{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
MRP Agro Ltd is Rated Sell
19 minutes ago
share
Share Via
Murudeshwar Ceramics Ltd is Rated Sell
19 minutes ago
share
Share Via
AMJ Land Holdings Ltd is Rated Strong Sell
19 minutes ago
share
Share Via
Duncan Engineering Ltd is Rated Sell
19 minutes ago
share
Share Via
Brigade Enterprises Ltd is Rated Strong Sell
19 minutes ago
share
Share Via
Zuari Industries Ltd is Rated Strong Sell
19 minutes ago
share
Share Via